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Abstract
Low-attenuation renal lesions on non-contrast computed tomography (CT) are often considered to be benign cysts without 
need for further imaging. However, the papillary subtype of renal cell carcinoma (RCC) may have similar radiographic charac-
teristics. A single-center retrospective review was therefore performed to identify extirpated papillary RCC (pRCC) specimens 
with correlation made to preoperative tumor imaging characteristics. A total of 108 pRCC specimens were identified of which 
84 (27 type I, 17 type 2, 40 unspecified) had CT imaging available for review. Non-contrast CT was available for 73 tumors with 
16 (22%) demonstrating Hounsfield units (HU) measurements fewer than 20 at baseline without differences between papillary 
subtypes. Mean attenuation following contrast administration was similar between papillary subtypes (45 HU for type 1 pRCC 
and 49 HU for type 2). This study highlights that pathologically proven pRCC is a heterogeneous entity in terms of density on 
preoperative CT imaging. A non-contrast CT scan with HU fewer than 20 may not be an adequate evaluation for incidental renal 
masses, as over 1 in 5 pRCCs demonstrate lower attenuation than this cutoff. Further study is needed to identify the appropriate 
role of ancillary imaging in the workup of seemingly benign-appearing renal lesions.
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Introduction
Renal lesions are common incidental findings on computed 
tomography, seen in 14% of unenhanced colonographic 
computed tomography (CT) (1). The attenuation of normal 
renal parenchyma on unenhanced CT typically ranges from 
30 to 40 Hounsfield units (HU). Despite a broad differential 
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diagnosis of both benign and malignant entities, a high den-
sity lesion measuring 40–70 HU is often considered to be a 
solid renal neoplasm with the majority having a malignant 
diagnosis (2). In the management of an incidental renal mass 
on unenhanced CT, homogeneous lesions with low attenua-
tion, typically defined as fewer than 20 HU, are frequently 
considered to be cystic lesions with low likelihood of being 
renal cell carcinoma (RCC) (1, 3). Thus, current guidelines 
recommend that a renal mass measuring fewer than 20 HU 
on non-contrast CT does not require further evaluation (4).
With respect to RCC, the papillary histological subtype 
accounts for approximately 10–15% of all RCCs and typi-
cally portends a better prognosis when compared to clear cell 
carcinomas. Papillary RCC (pRCC) may be classified as ei-
ther a type 1 or type 2 lesion (5). In terms of cytogenetic and 
molecular tumor profiling, when compared to type 1 lesions, 
type 2 pRCC tumors show a greater expression of vascular 
endothelial growth factor (VEGF) in the tumor epithelium 
and endothelium (6). Consequently, type 2 pRCC tumors 
are commonly associated with higher T stage, nodal and dis-
tant metastasis, higher grade, and higher degree of necrosis. 
These aggressive clinicopathological features along with the 
significantly higher microvascular invasion observed in type 
2 lesions are also associated with worse outcomes when com-
pared with type I (7, 8).
pRCC may present as a low-attenuation tumor on CT due 
to differences in the intratumoral vascularity and microvessel 
density. These differences enable clinicians to distinguish it 
from other types of RCC. However, there is a paucity of data 
directly delineating the frequency with which pRCC presents 
as a low-attenuation mass on non-contrast CT. This study 
aims to describe the CT characteristics of pRCC and to com-
pare the differences between type 1 and type 2 pRCC, as well 
as suggests the role of ancillary imaging to better address this 
imaging conundrum.
Materials and Methods
Radical and partial nephrectomies performed between July 
2007 and July 2017 at a single tertiary care academic medical 
center were retrospectively reviewed following IRB approval. 
Pathology reports were reviewed for all patients with pT1 or 
pT2 disease to identify cases with a histologically confirmed 
diagnosis of pRCC. Patients with preoperative renal CT im-
aging within 6 months of surgery were included for analysis. 
Exclusion criteria included the presence of multiple RCC 
types on pathologic specimen, inability to correlate pathol-
ogy report with preoperative imaging when multiple lesions 
were present, and unavailability of preoperative CT scans for 
independent review.
In all cases, four CT scan phases were analyzed to obtain 
renal tumor characteristics—non-contrast, corticomedullary, 
nephrographic, and pyelographic. Approximate times follow-
ing intravenous contrast for the contrast phases were 30 s, 
100 s, and 10 min, respectively, although there were minor 
variations. CT phases were available in various combinations 
as preoperative imaging selection was patient-dependent. 
For each phase, the renal tumor was assessed for maximum 
dimension in millimeters in all projections. The tumor was 
then assessed for density in the axial projection by selecting 6 
evenly spaced axial regions and using the imaging software to 
calculate HU. These six values were averaged and recorded. 
This method has been utilized previously in the literature and 
represents a real-world approach clinicians employ when re-
viewing CT imaging. Preliminary comparisons between using 
six evenly spaced regions versus all regions confirmed the va-
lidity of this approach. Tumors were grouped in increments 
of 10 HU to determine the frequency of observed preopera-
tive imaging density.
Differences in papillary subtype characteristics were com-
pared using two-tailed t-tests.
Results
Between July 2007 and July 2017, a total of 57 radical ne-
phrectomies and 67 partial nephrectomies were performed at 
our institution for a combined 124 pathologically confirmed 
cases of papillary RCC (Table 1); 16 of these specimens con-
tained other additional renal cell carcinoma types and were 
excluded. Of the 108 remaining patients, 84 (70% women, 
average age 62 years) had preoperative CT imaging available 
for review. Of these, 27 were reported on pathology to repre-
sent type 1 papillary RCC, 17 were type 2, and 40 were un-
specified. The median largest tumor dimension was 39.5 mm, 
ranging from 18 to 170 mm.
HU measurements on preoperative CT scan varied widely 
within all four imaging phases analyzed (Figure 1). Mean 
HU at 30 s, 100 s, and 10 min were 41 (standard deviation 
[SD] 17, range 7 to 91), 46 (SD 21, range 8 to 97), and 47 (SD 
17, range 20 to 101). The mean non-contrast attenuation was 
27 HU (SD 10, range −6 to 50) for the 73 tumors for which 
a non-contrast phase was available. Of these, three (4%) had 
HU measuring less than 10; 15 (21%) had HU measuring less 
than 20; and 45 (62%) had HU measuring less than 30. Nine 
(60%) of the 15 tumors with HU measuring fewer than 20 
were clinical stage T1 or T2; five were papillary type 1; three 
were papillary type 2; and seven were unspecified.
On non-contrast imaging, mean HU was 25 for papillary 
type 1 tumors and 27 for type 2 tumors. There was no signifi-
cant difference on two-tailed t-test in attenuation between type 
1 and type 2 tumors (P=0.67). At the 30-s contrast-enhanced 
phase, mean HU was 37 for type 1 tumors and 49 for type 2 
tumors; this difference was also not significant (P=0.06).
Discussion
We present data describing the frequent occurrence of low- 
attenuation pRCC on non-contrast CT. We found that over 
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Table 1: Patient and tumor characteristics.
Total patients with pRCC 124
Radical nephrectomies 57
Partial nephrectomies 67
Patients with exclusively pRCC 108
Patients with CT available 84
Patient age (mean, range) 62 20 to 94
Female gender (#, %) 59 70%
Type 1 pRCC (#, %) 27 32%
Type 2 pRCC (#, %) 17 20%
Type unspecified pRCC (#, %) 40 48%
Tumor size (mm, range) 39.5 18 to 170
Noncontrast HU<10 (#, %) 3 4%
Noncontrast HU<20 (#, %) 15 21%
Noncontrast HU<30 (#, %) 45 62%
Noncontrast HU (mean, SD, range)  27 10 −6 to 50
30-s contrast HU (mean, SD, range)  41 17 7 to 91
100-s contrast HU (mean, SD, range)  46 21 8 to 97
10-min contrast HU (mean, SD, range)  47 17 20 to 101
pRCC, Papillary renal cell carcinoma; CT, computed tomography; HU, Hounsfield units; SD, standard deviation.
Figure 1: Distribution of Hounsfield unit measurements for four phases of CT imaging of papillary RCC tumors.
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20% of pRCC lesions measured fewer than 20 HU. These 
 results suggest that a renal mass with non-contrast CT demon-
strating fewer than 20 HU may not be an adequate evaluation 
for incidental renal masses to forego further workup.
CT remains the first-line imaging modality for the charac-
terization of renal masses (9). A proportion of RCC, more 
specifically pRCC, are hypo-enhancing and may show in-
determinate range (10–20 HU) or even absent attenuation 
(fewer than 10 HU) on multi-phase CT given their hypo-
vascular and homogenous nature (10). pRCC characteris-
tically demonstrates gradual progressive enhancement. In a 
retrospective study consisting of 27 pRCCs, Dilauro et al. 
compared contrast-enhanced CT with magnetic resonance 
imaging (MRI) for the diagnosis of pRCC. They demon-
strated that only a small number of pRCCs have indeter-
minate enhancement on CT when a renal protocol is used. 
Specifically, on unenhanced CT, attenuation of pRCCs was 
similar to that of hemorrhagic or proteinaceous cysts, with a 
mean attenuation of 35.7 HU (range 19 to 66) (11). Schieda 
et al. determined the mean attenuation for 27 papillary tu-
mors to be approximately 35 HU on unenhanced CT, with 
none having attenuation between −10 and 20 (12). These ob-
servations contrast with our study, which found that greater 
than 20% of papillary masses measured fewer than 20 HU 
on non-contrast CT. This finding highlights the potential of 
missing clinically meaningful tumors with the current prac-
tice of foregoing workup for a hypoenhancing lesion.
The reason for the discrepancy between our findings and 
previous literature is unclear. One possible explanation may 
be related to the retrospective single-institution nature of 
the study. If  our center’s threshold for recommending ex-
tirpative therapy differs from elsewhere, we may be cap-
turing more low-density papillary tumors in our data set. 
Additionally, as CT technology, and other modalities such 
as ultrasound, continues to improve, more and more subtle 
lesions may be picked up, leading to their surgical removal. 
Finally, our sample size is several times greater than that of 
previous studies.
Types 1 and 2 pRCC can be distinguished pathologically. 
Type 1 tumors are characterized by a single layer of  small 
cells with scant cytoplasm, whereas type 2 lesions contain 
high nuclear-grade cells with abundant eosinophilic cy-
toplasm, coinciding with considerably poorer prognostic 
outcomes (13). However, from an imaging standpoint, we 
found similarity between type 1 and 2 pRCC, consistent 
with prior study (14).
There are no large studies describing specific distinguish-
ing features between types 1 and 2 pRCC. However, Yamada 
et al. conducted a retrospective review of pRCC patients, 
aiming to elaborate the unique CT features for each type 
of pRCC. They showed that type 1 tumors have more dis-
tinct margins and homogenous density than type 2 tumors, 
while both tumors were noted to show minimal enhance-
ment. Specifically, the mean attenuation on non-contrast 
CT did not differ significantly between the two types, with 
a recorded measure of 34.6 and 38.4 HU for type 1 and 2 
tumors, respectively (15). Compared to type 1 tumors, type 
2 tumors showed slightly higher mean relative enhancement 
ratios during the corticomedullary and nephrogenic phase, 
although these changes were not significant. In our study, the 
imaging characteristics for types 1 and 2 tumors were com-
parable, as we did not find a statistically significant mean at-
tenuation on noncontrast imaging or within contrast phases, 
consistent with the literature to date.
With improvements in diagnostic imaging modalities, 
the future directions in the evaluation of  the renal mass 
are trending towards the use of  MRI. This is thought to be 
attributable in part to an increased concern with radiation 
exposure associated with CT scans (16). In today’s practice, 
the American College of  Radiology rates MRI compara-
ble to CT for the evaluation of  indeterminate renal masses 
(17). Some studies suggest that MRI is the best modality 
for providing information to diagnose RCC subtypes as it 
enables high-quality histopathological characterization of 
renal masses (18). Specifically, for pRCC, Chiarello et al. 
conducted a systematic review and meta-analysis to delin-
eate the diagnostic performance of  MRI in differentiating 
pRCC from other masses (19). Their study compared 275 
pRCC lesions with 758 other renal masses. The results sug-
gested that MRI has a strong sensitivity and specificity for 
quantitative enhancement for differentiating pRCC from 
other tumors, particularly during the corticomedullary 
phase (19). In our study, 31 of  the 108 (29%) pRCC tumors 
had preoperative MRI imaging available, with 24 of  these 
31 cases (77%) in the more contemporary time period. Thus, 
although our study is not focused on the implications of 
MRI in the evaluation of  RCC, it is clear that MRI is in-
creasingly playing a more significant role in RCC imaging 
at our institution.
Our study findings are limited due to the retrospective na-
ture of the study. All patients did not undergo a standardized 
imaging workup prior to surgery, and thus, not all CT im-
aging phases are available for each lesion. As the papillary 
subtype represents only about 20% of all RCC, our sample 
size is limited. Furthermore, pathologic diagnoses may vary 
among pathologists, and not all specimens were specified as 
type 1 or type 2.
Conclusion
PRCC is a heterogeneous entity. Current clinical practice 
entails foregoing further workup for renal lesions measuring 
fewer than 20 HU on noncontrast CT. This study demon-
strates that over 20% of pRCC measures at fewer than 20 
HU, suggesting that this criterion may not yield adequate 
evaluation for an incidental renal mass. Further research will 
help better define the role of ancillary imaging.
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